Source 1primary paper2025MED
Toolkit/AAV-exosomes
AAV-exosomes
Also known as: hybrid systems
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Future directions focus on AI-driven vector design, hybrid systems (AAV-exosomes), and standardized manufacturing to achieve "single-dose, lifelong cure" paradigms for muscular disorders.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
No mechanism tags yet.
Techniques
Computational DesignTarget processes
manufacturingValidation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
AAV-based therapies such as Elevidys for DMD and Zolgensma for SMA demonstrate functional improvements, although immune responses and hepatotoxicity remain concerns.
Clinically, AAV-based therapies (e.g., Elevidys® for DMD, Zolgensma® for SMA) demonstrate functional improvements, though immune responses and hepatotoxicity remain concerns.
Non-viral vectors including liposomes, polymers, and exosomes offer advantages in cargo capacity, biocompatibility, and scalable production, but they face challenges in transduction efficiency and endosomal escape.
Non-viral vectors (liposomes, polymers, exosomes) offer advantages in cargo capacity (delivering full-length dystrophin), biocompatibility, and scalable production but face challenges in transduction efficiency and endosomal escape.
AAV vectors dominate clinical applications for gene therapy in hereditary skeletal myopathies because they efficiently transduce post-mitotic myofibers and support sustained transgene expression.
Adeno-associated virus (AAV) vectors dominate clinical applications due to their efficient transduction of post-mitotic myofibers and sustained transgene expression.
AAV engineering innovations including capsid modification, self-complementary genomes, and tissue-specific promoters such as MHCK7 enhance muscle tropism while mitigating immunogenicity and off-target effects.
Innovations in AAV engineering, such as capsid modification (chemical conjugation, rational design, directed evolution), self-complementary genomes, and tissue-specific promoters (e.g., MHCK7), enhance muscle tropism while mitigating immunogenicity and off-target effects.
Future targeted gene delivery strategies for muscular disorders emphasize AI-driven vector design, AAV-exosome hybrid systems, and standardized manufacturing to pursue single-dose lifelong therapeutic benefit.
Future directions focus on AI-driven vector design, hybrid systems (AAV-exosomes), and standardized manufacturing to achieve "single-dose, lifelong cure" paradigms for muscular disorders.
Approval Evidence
1 source1 linked approval claimfirst-pass slug aav-exosomes
Future directions focus on AI-driven vector design, hybrid systems (AAV-exosomes), and standardized manufacturing to achieve "single-dose, lifelong cure" paradigms for muscular disorders.
Source:
future directionsupports
Future targeted gene delivery strategies for muscular disorders emphasize AI-driven vector design, AAV-exosome hybrid systems, and standardized manufacturing to pursue single-dose lifelong therapeutic benefit.
Future directions focus on AI-driven vector design, hybrid systems (AAV-exosomes), and standardized manufacturing to achieve "single-dose, lifelong cure" paradigms for muscular disorders.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.